Appendix II — A — Decisions Cited — A
Ninth Edition, Revision 01.2024
[ Editor Note: Opinions of the Patent Trial and Appeal Board or its predecessor organizations (Board) made available to the public after the Board first published Standard Operating Procedure 2 in 1994 (addressing the publication of Board opinions and the designation of such opinions as precedential) that (1) expressly indicate that the opinion is binding precedent of the Board or (2) are identified as binding precedent on the Board’s Precedential opinion website ( www.uspto.gov/patents-application-process/appealing -patent-decisions/decisions-and-opinions/precedential ) are precedential and binding authority. Prior to 1994, a decision by the Board was considered binding on panels of the Board only if the opinion was authorized by the Board to be published. See Ex parte Holt, 19 USPQ2d 1211 (Bd.Pat. App. & Int. 1991).]
Editor Note: When possible, parallel citations to the United States Reports or Federal Reporter and the United States Patent Quarterly (USPQ) are provided and include pinpoint pages, if appropriate. However, decisions of the U.S. Supreme Court and the U.S. Court of Appeals for the Federal Circuit published after July 11, 2022, no longer contain a pinpoint page for the USPQ citations.
A, Ex parte, 17 USPQ2d 1716 (Bd. Pat. App. & Inter. 1990) 716.02(a) , 2131.02
Abacab International Computers Ltd., In re, 21 USPQ2d 1078 (Comm’r Pat. 1987) 323.01(b)
Abbott Diabetes Care Inc., In re, 696 F.3d 1142, 104 USPQ2d 1337 (Fed. Cir. 2012) 2111.01
Abbott Laboratories v. Baxter Pharmaceutical Products Inc., 334 F.3d 1274, 67 USPQ2d 1191 (Fed. Cir. 2003) 803.02 , 2111.03 , 2117 , 2173.05(h)
Abbott Laboratories v. Geneva Pharmaceuticals, Inc., 182 F.3d 1315, 51 USPQ2d 1307 (Fed. Cir. 1999) 2112 , 2133.03(c)
Abbott Labs. v. Sandoz, Inc., 544 F.3d 1341, 89 USPQ2d 1161 (Fed. Cir. 2008) 2143
Abbott Labs. v. Syntron Bioreseach, Inc., 334 F.3d 1343, 67 USPQ2d 1337 (Fed. Cir. 2003) 2286
AbbVie Duetschland GmbH & Co., KG v. Janssen Biotech, Inc., 759 F.3d 1285, 111 USPQ2d 1780 (Fed. Cir. 2014) 2163 , 2163.05
AbbVie Inc. v. Kennedy Institute of Rheumatology Trust, 764 F.3d 1366, 112 USPQ2d 1001 (Fed. Cir. 2014) 804 , 804.02
Abele, In re, 684 F.2d 902, 214 USPQ 682 (CCPA 1982) 2106.04(a)(2) , 2184
Acceleration Bay, LLC v. Activision Blizzard Inc., 908 F.3d 765, USPQ2d 1507 (Fed. Cir. 2018) 2128.01
Accenture Global Services v. Guidewire Software, Inc., 728 F.3d 1336, 108 USPQ2d 1173 (Fed. Cir. 2013) 2106.04(a)(2)
ACCO Brands Corp. v. Fellowes, Inc., 813 F.3d 1361, 117 USPQ2d 1951 (Fed. Cir. 2016) 2142
Ackermann, In re, 444 F.2d 1172, 170 USPQ 340 (CCPA 1971) 2190
Acorda Therapeutics, Inc. v. Roxane Lab., Inc., 903 F.3d 1310, 128 USPQ2d 1001 (Fed. Cir. 2018) 2143.02
Actelion Pharm. v. Matal, 881 F.3d 1339, 125 USPQ2d 1585 (Fed. Cir. 2018) 2731
Actelion Pharmaceuticals Ltd v. Mylan Pharmaceuticals Inc., 85 F.4th 1167, 2023 USPQ2d 1314 (Fed. Cir. 2023) 2111.01 , 2131.01 , 2141
Adapt Pharma Operations Ltd. v. Teva Pharms. USA, Inc., 25 F.4th 1354, 2022 USPQ2d 144 (Fed. Cir. 2022) 2141
Adler v. Kluver, 159 USPQ 511 (Bd. Pat. Inter. 1968) 715.05
Aelony v. Arni, 547 F.2d 566, 192 USPQ 486 (CCPA 1977) 2155.06 , 2301.03
AFG Industries, Inc. v. Cardinal IG Company, Inc., 239 F.3d 1239, 57 USPQ2d 1776 (Fed. Cir. 2001) 2111.03
A.F. Stoddard & Co. v. Dann, 564 F.2d 556, 195 USPQ 97 (D.C. Cir. 1977) 1412.04
Affidavit Filed After Final Rejection, In re, 152 USPQ 292, 1966 C.D. 53 (Comm’r Pat. 1966) 2265
Affinity Labs of Tex. v. Amazon.com, 838 F.3d 1266, 120 USPQ2d 1210 (Fed. Cir. 2016) 2106.05(a) , 2106.07(a)
Affinity Labs of Tex. v. DirecTV, LLC, 838 F.3d 1253, 120 USPQ2d 1201 (Fed. Cir. 2016) 2106.05(a) , 2106.05(f) , 2106.05(h)
Agilent Techs., Inc. v. Affymetrix, Inc., 567 F.3d 1366, 91 USPQ2d 1161 (Fed. Cir. 2009) 2301.03 , 2304.02(d)
Agrizap, Inc. v. Woodstream Corp., 520 F.3d 1337, 86 USPQ2d 1110 (Fed. Cir. 2008) 804 , 2143
Ahlert, In re, 424 F.2d 1088, 165 USPQ 418 (CCPA 1970) 1207.03(a) , 2144.03
Ahrens v. Grey, 1931 C.D. 9, 402 O.G. 261 (Bd. App. 1929) 213.03
Airbus S.A.S. v. Firepass Corp., 941 F.3d 1374, 2019 USPQ2d 430083 (Fed. Cir. 2019) 2141.01(a)
Ajinomoto Co. v. Archer-Daniels-Midland Co., 228 F.3d 1338, 56 USPQ2d 1332 (Fed. Cir. 2000), cert. denied, 121 S.Ct 1957 (2001) 2402
AK Steel Corp. v. Sollac, 344 F.3d 1234, 68 USPQ2d 1280 (Fed. Cir. 2003) 2111.03 , 2161.01 , 2163 , 2164.08
Akeva LLC v. Nike, Inc., 817 Fed. Appx. 1005, 2020 USPQ2d 10797 (Fed. Cir. 2020) 2163
Akron Brass Co. v. Elkhart Brass Mfg. Co., Inc., 353 F.2d 704, 147 USPQ 301 (7th Cir. 1965) 2133.03(e)(1)
Aktiebolaget Astra v. Lehman, 71 F.3d 1578, 37 USPQ2d 1212 (Fed. Cir. 1995) 2757
Akzo N.V. v. International Trade Comm’n, 808 F.2d 1471, 1 USPQ2d 1241 (Fed. Cir. 1986) 2131.02
Alappat, In re, 33 F.3d 1526, 31 USPQ2d 1545 (Fed. Cir. 1994) 2106 , 2106.05(a)
Albertson, In re, 332 F.2d 379, 141 USPQ 730 (CCPA 1964) 2116.01
Albrecht, In re, 514 F.2d 1389, 185 USPQ 585 (CCPA 1975) 2144.08 , 2144.09 , 2145
Alcon Laboratories Inc., In re, 13 USPQ2d 1115 (Comm’r Pat. & Tm. 1989) 2751 , 2755.01
Alice Corp. Pty. Ltd. v. CLS Bank Int'l, 573 U.S. 208, 110 USPQ2d 1976 (2014) 2104 , 2106 , 2106.04 , 2106.04(a)(1) , 2106.04(a)(2) , 2106.04(d) , 2106.05 , 2106.05(a) , 2106.05(b) , 2106.05(d) , 2106.05(e) , 2106.05(f) , 2106.07(b)
Allen, Ex parte, 2 USPQ2d 1425 (Bd. Pat. App. & Inter. 1987) 2105
Allen Eng’g Corp. v. Bartell Indus., Inc., 299 F.3d 1336, 63 USPQ2d 1769 (Fed. Cir. 2002) 2133.03(e) , 2133.03(e)(4)
Allen & Hansbury Ltd., In re, 227 USPQ 955 (Comm’r Pat. & Tm. 1985) 2756
Aller, In re, 220 F.2d 454, 105 USPQ 233 (CCPA 1955) 2144.05
Allergan, Inc. v. Sandoz Inc., 796 F.3d 1293, 115 USPQ2d 2012 (Fed. Cir. 2015) 2144.05 , 2164.02
Allied Erecting v. Genesis Attachments, 825 F.3d 1373, 119 USPQ2d 1132 (Fed. Cir. 2016) 2141.02 , 2143.01
AllVoice Computing PLC v. Nuance Commc’ns, Inc., 504 F.3d 1236, 84 USPQ2d 1886 (Fed. Cir. 2007) 2181
Alpert v. Slatin, 305 F.2d 891, 134 USPQ 296 (CCPA 1962) 2138.04
Al-Site Corp. v. VSI International Inc., 174 F.3d 1308, 50 USPQ2d 1161 (Fed. Cir. 1999) 2181 , 2183
Altana Pharma AG v. Teva Pharm. USA, Inc., 566 F.3d 999, 91 USPQ2d 1018 (Fed. Cir. 2009) 2143
Altiris Inc. v. Symantec Corp., 318 F.3d 1363, 65 USPQ2d 1865 (Fed. Cir. 2003) 2111.01 , 2181
Alton, In re, 76 F.3d 1168, 37 USPQ2d 1578 (Fed. Cir. 1996) 1504.04 , 2145 , 2163 , 2163.04 , 2164.05
Altoona Publix Theatres v. American Tri-Ergon Corp., 294 U.S. 477, 24 USPQ 308 (1935) 1490
ALZA Corp. v. Andrx Pharms., LLC, 603 F.3d 935, 94 USPQ2d 1823 (Fed. Cir. 2010) 2161.01
Alza Corp. v. Mylan Laboratories, Inc., 464 F.3d 1286, 80 USPQ2d 1001 (Fed. Cir. 2006) 2143
Am. Acad. of Sci. Tech. Ctr., In re, 367 F.3d 1359, 70 USPQ2d 1827 (Fed. Cir. 2004) 804 , 2111 , 2111.01 , 2173.01
Amazon.com v. Barnesandnoble.com, 73 F. Supp. 2d 1228, 53 USPQ2d 1115 (W.D. Wash. 1999) 2128
Amdocs (Israel) Ltd. v. Openet Telecom, Inc., 841 F.3d 1288, 120 USPQ2d 1527 (Fed. Cir. 2016) 2106 , 2106.04(a) , 2106.05(a) , 2106.05(d)
American Infra-Red Radiant Co. v. Lambert Indus., 360 F.2d 977, 149 USPQ 722 (8th Cir. 1966) 2135.01
American Hoist & Derrick Co. v. Sowa & Sons, Inc., 725 F.2d 1350, 220 USPQ 763 (Fed. Cir. 1984) 410 , 2141
American Seating Co. v. USSC Group, Inc., 514 F.3d 1262, 85 USPQ2d 1683 (Fed. Cir. 2008) 2152.02(c)
Amgen Inc. v. Amneal Pharmaceuticals LLC, 945 F.3d 1368, 2020 USPQ2d 3197 (Fed. Cir. 2020) 2111.03 , 2117
Amgen, Inc. v. Chugai Pharmaceutical Co., 927 F.2d 1200, 18 USPQ2d 1016 (Fed. Cir. 1991) 2138 , 2138.04 , 2143.02 , 2163 , 2163.02 , 2164.08 , 2165.04 , 2173.05(b)
Amgen, Inc. v. Hoechst Marion Roussel, Inc., 126 F. Supp. 2d 69, 57 USPQ2d 1449 (D. Mass. 2001) 706.04
Amgen Inc. v. F. Hoffman-La Roche Ltd., 580 F.3d 1340, 92 USPQ2d 1289 (Fed. Cir. 2009) 1481.03 , 2113
Amgen v. Sanofi, 872 F.3d 1367, 124 USPQ2d 1354 (Fed. Cir. 2017) 804.03 , 2124 , 2136.03 , 2163
Amgen Inc. v. Sanofi, Aventisub LLC, 987 F.3d 1080, 2021 USPQ2d 169 (Fed. Cir. 2021) 2164.01(a) , 2164.06
Amgen Inc. et al. v. Sanofi et al., 598 U.S. 594, 143 S. Ct. 1243, 215 L. Ed. 2d 537, 2023 U.S.P.Q.2d 602 (2023) 2164.01 , 2164.01(a) , 2164.02 , 2164.06 , 2164.08
Amini Innovation Corp. v. Anthony California Inc., 439 F.3d 1365, 78 USPQ2d 1147 (Fed. Cir. 2006) 1504.02
Amos, In re, 953 F.2d 613, 21 USPQ2d 1271 (Fed. Cir. 1991) 1412.01
Amp, In re, 212 USPQ 826 (Comm’r Pat. 1981) 2225
Amphenol Corp. v. Gen’l Time Corp., 397 F.2d 431, 158 USPQ 113 (7th Cir. 1968) 2133.03(e)(1)
Anchor Hocking Corp. v. Eyelet Specialty Co., 377 F. Supp 98, 183 USPQ 87 (D. Del. 1974) 1504.06
Anderson, Ex parte, 21 USPQ2d 1241 (Bd. Pat. App. & Inter. 1991) 2173.05(b)
Anderson, In re, 471 F.2d 1237, 176 USPQ 331 (CCPA 1973) 2163.07 , 2181
Anderson, In re, 1997 U.S. App. Lexis 167 (Fed. Cir. January 6, 1997) 2173.03
Anderson’s-Black Rock, Inc. v. Pavement Salvage Co., 396 U.S. 57, 163 USPQ 673 (1969) 716.01(a) , 2141 , 2143 , 2143.01
Anderson v. Crowther, 152 USPQ 504 (Bd. Pat. Inter. 1965) 2138.06
Andresen, Ex parte, 212 USPQ 100 (Bd. Pat. App. & Inter. 1981) 2004 , 2137 , 2141.01
Andrew Corp. v. Gabriel Electronics, 847 F.2d 819, 6 USPQ2d 2010 (Fed. Cir. 1988) 2173.05(b)
Angiotech Pharms. Inc. v. Lee, 191 F. Supp. 3d 509 (E.D. Va. 2016) 2751
Angstadt, In re, 537 F.2d 498, 190 USPQ 214 (CCPA 1976) 2164.01 , 2164.06 , 2164.08(b)
Antares Pharma Inc. v. Medac Pharma Inc. and Medac GMBH, 771 F.3d 1354, 112 USPQ2d 1865 (Fed. Cir. 2014) 1412.01
Anthony, Ex parte, 230 USPQ 467 (Bd. App. 1982), aff’d 770 F.2d 182 (Fed. Cir. 1985) (table) 1490
Anthony, In re, 414 F. 2d 1383, 162 USPQ 594 (CCPA 1969) 2107.01 , 2107.03
Antonie, In re, 559 F.2d 618, 195 USPQ 6 (CCPA 1977) 2141.02 , 2144.05
Antor Media Corp., In re, 689 F.3d 1282, 103 USPQ2d 1555 (Fed. Cir. 2012) 2121
Aoyama, In re, 656 F.3d 1293, 99 USPQ2d 1936 (Fed. Cir. 2011) 2103 , 2181 , 2185
Apex Inc. v. Raritan Computer, Inc., 325 F.3d 1364, 66 USPQ2d 1444 (Fed. Cir. 2003) 2181
Apotex v. UCB, Inc., 763 F.3d 1354, 112 USPQ2d 1081 (Fed. Cir. 2014) 2004
Appeal, Decided 9/3/68, Ex parte, 866 O.G. 16 (Bd. App. 1968) 1504.02
Appeal No 239-48, 151 USPQ 711, 1966 C.D. 22, 833 O.G. 10 (Bd. App. 1965) 1504.02
Appeal No. 242-47, Ex parte, 196 USPQ 828 (Bd. App. 1976) 2135.01
Appeal No. 315-40, Ex Parte, 152 USPQ 71 (Bd. App. 1965) 1504.05
Apple, Inc. v. Ameranth, Inc., 842 F.3d 1229, 120 USPQ2d 1844 (Fed. Cir. 2016) 2106.04(a)(1) , 2106.05(a) , 2106.05(d) , 2106.05(f) , 2106.05(g) , 2106.07(a)
Apple Inc. v. Corephotonics, Ltd., 81 F.4th 1353, 2023 USPQ2d 1056 (Fed. Cir. 2023) 2111.01
Apple Inc. v. Samsung Elecs. Co., 786 F.3d 983, 114 USPQ2d 1953 (Fed. Cir. 2015) 1504.02
Apple Inc. v. Samsung Elecs. Co., 839 F.3d 1034, 120 USPQ2d 1400 (Fed. Cir. 2016) 2141
Application Filed Nov. 16, 1945, In re, 89 USPQ 280, 1951 C.D. 1, 646 O.G. 5 (Comm’r Pat. 1951) 904.01(a)
Application of Takao, 17 USPQ2d 1155 (Comm’r Pat. 1990) 711.03(c)
Application Papers Filed Sept. 10, 1954, In re, 108 USPQ 340 (Comm’r Pat. 1955) 409.03(c)
Applied Materials Inc. v. Advanced Semiconductor Materials, 98 F.3d 1563, 40 USPQ2d 1481 (Fed. Cir. 1996) 804.01 , 804.02 , 804.04
Applied Materials Inc. v. Gemini Research Corp., 835 F.2d 279, 15 USPQ2d 1816 (Fed. Cir. 1988) 2136.05
Arendi v. Apple, 832 F.3d 1355, 119 USPQ2d 1822 (Fed. Cir. 2016) 2141 , 2143 , 2144.03 , 2144.05
Argoudelis, Ex parte, 157 USPQ 437 (Bd. App. 1967) 1214.03
Argoudelis, In re, 434 F.2d 1390, 168 USPQ 99 (CCPA 1970) 2164.06 , 2164.06(a) , 2402
Ariad Pharms., Inc. v. Eli Lilly & Co., 598 F.3d 1336, 94 USPQ2d 1161 (Fed. Cir. 2010) 1504.04 , 2161 , 2161.01 , 2163 , 2163.03 , 2173.05(g) , 2181
Ariad Pharm. Inc v. Matal, 283 F. Supp. 3d 503 (E.D. Va. 2018) 2731
Ariosa Diagnostics, Inc. v. Sequenom, Inc., 788 F.3d 1371, 115 USPQ2d 1152 (Fed. Cir. 2015) 2106.04 , 2106.04(a)(1) , 2106.04(b) , 2106.04(c) , 2106.07(b)
Aristocrat Technologies Australia PTY Ltd. v. International Game Technology, 521 F.3d 1328, 86 USPQ2d 1235 (Fed. Cir. 2008) 2163 , 2181
Aristocrat Technologies Australia Pty Ltd. v. International Game Technology, 543 F.3d 657, 88 USPQ2d 1458 (Fed. Cir. 2008) 2268
Armbruster, In re, 512 F. 2d 676, 185 USPQ 152 (CCPA 1975) 608.01(b) , 2161 , 2181
Armour & Co. v. Swift & Co., 466 F.2d 767, 175 USPQ 70 (7th Cir. 1972) 2001.06(b)
Armstrong, In re, 280 F.2d 132, 126 USPQ 281 (CCPA 1960) 716.02(e)
Arnold Partnership v. Dudas, 362 F.3d 1338, 70 USPQ2d 1311 (Fed. Cir. 2004) 2751
Arnott, In re, 19 USPQ2d 1049 (Comm’r Pat. 1991) 1481 , 1490
ArQule v. Kappos, 793 F. Supp. 2d 214 (D.D.C. 2011) 2732 , 2734
Arunachalam, In re, 709 Fed. Appx. 699 (Fed. Cir. 2017)(nonprecedential) 2259
Arzberger, In re, 112 F.2d 834, 46 USPQ 32 (CCPA 1940) 1601
Asahi/America Inc., In re, 68 F.3d 442, 37 USPQ2d 1204 (Fed. Cir. 1995) 715.07
Asano, Ex parte, 201 USPQ 315 (Bd. Pat. App. & Inter. 1978) 1503.02
Ashland Oil, Inc. v. Delta Resins & Refractories, Inc., 776 F.2d 281, 227 USPQ 657 (Fed. Cir. 1985) 716.01(b) , 716.01(c) , 2145
Aslanian, In re, 590 F.2d 911, 200 USPQ 500 (CCPA 1979) 2125
Association for Molecular Pathology v. Myriad Genetics, Inc., 569 U.S. 576, 106 USPQ2d 1972 (2013) 2104 , 2105 , 2106 , 2106.04 , 2106.04(b) , 2106.04(c)
Atlantic Thermoplastics Co. v. Faytex Corp., 970 F.2d 834, 23 USPQ2d 1481 (Fed. Cir. 1992) 2133.03(b) , 2133.03(c)
Atlas Powder Co. v. E.I. duPont de Nemours & Co., 750 F.2d 1569, 224 USPQ 409 (Fed. Cir. 1984) 2111.03 , 2164.01 , 2164.02 , 2164.08(b)
Atlas Powder Co. v. IRECO, Inc., 190 F.3d 1342, 51 USPQ2d 1943 (Fed. Cir. 1999) 2112 , 2131.01 , 2131.05
Atmel Corp. v. Information Storage Devices Inc., 198 F.3d 1374, 53 USPQ2d 1225 (Fed. Cir. 1999) 2163 , 2181
Atofina v. Great Lakes Chemical Corp, 441 F.3d 991, 78 USPQ2d 1417 (Fed. Cir. 2006) 2131.03
Attig, Ex parte, 7 USPQ2d 1092 (Bd. Pat. App. & Inter. 1986) 2173.05(b)
Auto. Techs. Int’l, Inc. v. BMW of N. Am.,Inc., 501 F.3d 1274, 84 USPQ2d 1108 (Fed. Cir. 2007) 2161.01 , 2164.06(a)
Autogiro Co. of America v. United States, 384 F.2d 391,155 USPQ 697 (Ct. Cl. 1967) 2163
Aventis Pharma S.A. v. Hospira, Inc., 675 F.3d 1324, 102 USPQ2d 1445 (Fed. Cir. 2012) 2141
Avanir Pharm. v. Kappos, No. 1:12cv69 (E.D. Va. March 21, 2012) 2751
Aventis Pharma Deutschland v. Lupin Ltd., 499 F.3d 1293, 84 USPQ2d 1197 (Fed. Cir. 2007) 2143 , 2144.09
Avia Group International, Inc. v. L.A. Gear California, Inc., 853 F.2d 1557, 7 USPQ2d 1548 (Fed. Cir. 1988) 1504.01(c) , 1504.03
Axonics, Inc. v. Medtronic, Inc., 73 F.4th 950, 2023 USPQ2d 795 (Fed. Cir. 2023) 2143.01 , 2143.03
Ayers, Ex parte, 108 USPQ 444 (Bd. App. 1955) 608.04(a)
Azar v. Burns, 188 USPQ 601 (Bd. Pat. Inter. 1975) 2138.05
Cited authority
- 716.02(a) Evidence Must Show Unexpected Results
- 2131.02 Genus-Species Situations
- 323.01(b) Typographical Errors in Recorded Assignment Document
- 2111.01 Plain Meaning
- 803.02 Election of Species Requirements – Markush Claims
- 2111.03 Transitional Phrases
- 2117 Markush Claims
- 2173.05(h) Alternative Limitations
- 2112 Requirements of Rejection Based on Inherency; Burden of Proof
- 2133.03(c) The “Invention”
- 2143 Examples of Basic Requirements of a Prima Facie Case of Obviousness
- 2286 Ex Parte Reexamination and Litigation Proceedings
- 2163 Guidelines for the Examination of Patent Applications Under the 35 U.S.C. 112(a) or Pre-AIA 35 U.S.C. 112, first paragraph, “Written Description” Requirement
- 2163.05 Changes to the Scope of Claims
- 804 Definition of Double Patenting
- 804.02 Avoiding a Double Patenting Rejection
- 2106.04(a)(1) Examples of Claims That Do Not Recite Abstract Ideas
- 2184 Determining Whether an Applicant Has Met the Burden of Proving Nonequivalence After a Prima Facie Case Is Made
- 2128.01 Level of Public Accessibility Required
- 2142 Legal Concept of Prima Facie Obviousness
- 2190 Prosecution Laches and Res Judicata
- 2143.02 Reasonable Expectation of Success Is Required
- 2731 Period of Adjustment
- 2131.01 Multiple Reference 35 U.S.C. 102 Rejections
- 2141 Examination Guidelines for Determining Obviousness Under 35 U.S.C. 103
- 715.05 U.S. Patent or Application Publication Claiming Same Invention
- 2155.06 Situations in Which an Affidavit or Declaration Is Not Available
- 2301.03 Interfering Subject Matter
- 1412.04 Correction of Inventorship By Reissue
- 2265 Extension of Time
- 2106.05(a) Improvements to the Functioning of a Computer or To Any Other Technology or Technical Field
- 2106.07(a) Formulating a Rejection For Lack of Subject Matter Eligibility
- 2106.05(f) Mere Instructions To Apply An Exception
- 2106.05(h) Field of Use and Technological Environment
- 2304.02(d) Adequate Written Description
- 1207.03(a) Determining Whether a Ground of Rejection is New
- 2144.03 Reliance on Common Knowledge in the Art or “Well Known” Prior Art
- 213.03 Time for Filing U.S. Nonprovisional Application
- 2141.01(a) Analogous and Nonanalogous Art
- 2402 The Deposit Rules
- 2161.01 Computer Programming, Computer Implemented Inventions, and 35 U.S.C. 112(a) or Pre-AIA 35 U.S.C. 112, First Paragraph
- 2164.08 Enablement Commensurate in Scope With the Claims
- 2133.03(e)(1) Commercial Exploitation
- 2757 Regulatory Agency Determination of the Length of the Regulatory Review Period
- 2106 Patent Subject Matter Eligibility
- 2116.01 Novel, Nonobvious Starting Material or End Product
- 2144.08 Obviousness of Species When Prior Art Teaches Genus
- 2144.09 Close Structural Similarity Between Chemical Compounds (Homologs, Analogues, Isomers)
- 2145 Consideration of Applicant’s Rebuttal Arguments and Evidence
- 2751 Eligibility Requirements
- 2755.01 Interim Extension of Patent Term During the Processing of the Application
- 2104 Requirements of 35 U.S.C. 101
- 2106.04 Eligibility Step 2A: Whether a Claim is Directed to a Judicial Exception
- 2106.04(a)(2) Abstract Idea Groupings
- 2106.04(d) Integration of a Judicial Exception Into A Practical Application
- 2106.05 Eligibility Step 2B: Whether a Claim Amounts to Significantly More
- 2106.05(b) Particular Machine
- 2106.05(d) Well-Understood, Routine, Conventional Activity
- 2106.05(e) Other Meaningful Limitations
- 2106.07(b) Evaluating Applicant’s Response
- 2105 Patent Eligible Subject Matter — Living Subject Matter
- 2133.03(e) Permitted Activity; Experimental Use
- 2133.03(e)(4) Factors Indicative of an Experimental Purpose
- 2756 Correspondence Between the USPTO and the Regulatory Agency
- 2144.05 Obviousness of Similar and Overlapping Ranges, Amounts, and Proportions
- 2164.02 Working and Prophetic Examples
- 2141.02 Differences Between Prior Art and Claimed Invention
- 2143.01 Suggestion or Motivation To Modify the References
- 2181 Identifying and Interpreting a 35 U.S.C. 112(f) or Pre-AIA 35 U.S.C. 112, Sixth Paragraph Limitation
- 2138.04 “Conception”
- 2183 Making a Prima Facie Case of Equivalence
- 1504.04 Considerations Under 35 U.S.C. 112
- 2163.04 Burden on the Examiner with Regard to the Written Description Requirement
- 2164.05 Determination of Enablement Based on Evidence as a Whole
- 1490 Disclaimers
- 2111 Claim Interpretation; Broadest Reasonable Interpretation
- 2173.01 Interpreting the Claims
- 2128 “Printed Publications” as Prior Art
- 2106.04(a) Abstract Ideas
- 2135.01 The Four Requirements of Pre-AIA 35 U.S.C. 102(d)
- 410 Representations to the U.S. Patent and Trademark Office
- 2152.02(c) In Public Use
- 2138 Pre-AIA 35 U.S.C. 102(g)
- 2163.02 Standard for Determining Compliance With the Written Description Requirement
- 2165.04 Examples of Evidence of Concealment
- 2173.05(b) Relative Terminology
- 706.04 Rejection of Previously Allowed Claims
- 1481.03 Correction of 35 U.S.C. 119 and 35 U.S.C. 120 Benefits
- 2113 Product-by-Process Claims
- 804.03 Commonly Owned Inventions of Different Inventive Entities; Non-Commonly Owned Inventions Subject to a Joint Research Agreement
- 2124 Exception to the Rule That the Reference Must be Prior Art
- 2136.03 Critical Reference Date
- 2164.01(a) Undue Experimentation Factors
- 2164.06 Quantity of Experimentation
- 2164.01 Test of Enablement
- 1504.02 Novelty
- 1412.01 Reissue Claims Must Be for Same General Invention
- 2225 Untimely Paper Filed Prior to Order under 35 U.S.C. 304
- 1504.06 Double Patenting
- 2163.07 Amendments to Application Which Are Supported in the Original Description
- 2173.03 Correspondence Between Specification and Claims
- 716.01(a) Objective Evidence of Nonobviousness
- 2138.06 “Reasonable Diligence”
- 2004 Aids to Compliance With Duty of Disclosure
- 2137 Pre-AIA 35 U.S.C. 102(f)
- 2141.01 Scope and Content of the Prior Art
- 2164.08(b) Inoperative Subject Matter
- 2107.01 General Principles Governing Utility Rejections
- 2107.03 Special Considerations for Asserted Therapeutic or Pharmacological Utilities
- 2121 Prior Art; General Level of Operability Required to Make a Prima Facie Case
- 2103 Patent Examination Process
- 2185 Related Issues Under 35 U.S.C. 112(a) or (b) and Pre-AIA 35 U.S.C. 112, First or Second Paragraphs
- 1504.05 Restriction
- 2106.05(g) Insignificant Extra-Solution Activity
- 904.01(a) Variant Embodiments Within Scope of Claim
- 711.03(c) Petitions Relating to Abandonment
- 409.03(c) Unavailable Legal Representative of Deceased Inventor
- 804.01 Prohibition of Nonstatutory Double Patenting Rejections Under 35 U.S.C. 121
- 804.04 Submission to Technology Center Director
- 2136.05 Overcoming a Rejection Under Pre-AIA 35 U.S.C. 102(e)
- 1214.03 Rehearing
- 2164.06(a) Examples of Enablement Issues-Missing Information
- 2163.03 Typical Circumstances Where Adequate Written Description Issue Arises
- 2173.05(g) Functional Limitations
- 2106.04(b) Laws of Nature, Natural Phenomena & Products of Nature
- 2106.04(c) The Markedly Different Characteristics Analysis
- 2268 Petition for Entry of Late Papers for Revival of Reexamination Proceeding
- 608.01(b) Abstract of the Disclosure
- 2161 Three Separate Requirements for Specification Under 35 U.S.C. 112(a) or Pre-AIA 35 U.S.C. 112, First Paragraph
- 2001.06(b) Information Relating to or From Copending United States Patent Applications
- 716.02(e) Comparison With Closest Prior Art
- 1481 Certificates of Correction - Applicant’s Mistake
- 2732 Reduction of Period of Adjustment of Patent Term
- 2734 Application for Patent Term Adjustment; Due Care Showing
- 2259 Res Judicata and Collateral Estoppel in Reexamination Proceedings
- 1601 Introduction: The Act, Scope, Type of Plants Covered
- 715.07 Facts and Documentary Evidence
- 1503.02 Drawing
- 716.01(b) Nexus Requirement and Evidence of Nonobviousness
- 716.01(c) Probative Value of Objective Evidence
- 2125 Drawings as Prior Art
- 2133.03(b) “On Sale”
- 2131.05 Nonanalogous or Disparaging Prior Art
- 2131.03 Anticipation of Ranges
- 1504.01(c) Lack of Ornamentality
- 1504.03 Nonobviousness
- 2143.03 All Claim Limitations Must Be Considered
- 608.04(a) Matter Not Present in Specification, Claims, or Drawings on the Application Filing Date
- 2138.05 “Reduction to Practice”